TERT c.3150 G > C (p.K1050N): a founder Ashkenazi Jewish variant associated with telomere biology disorders
de Andrade KCPapers in this archive, Pinto EMPapers in this archive, Zhao TPapers in this archive, Zeigler LPPapers in this archive, Kim JPapers in this archive, Giri NPapers in this archive, Haley JSPapers in this archive, McReynolds LJPapers in this archive, Florez-Vargas OPapers in this archive, Phillips AHPapers in this archive, Kriwacki RWPapers in this archive, Akinniyi SAPapers in this archive, Cohen SBPapers in this archive, Emerson MRPapers in this archive, Smelser DTPapers in this archive, Urban GMPapers in this archive, Fridman CPapers in this archive, Zambetti GPPapers in this archive, Bryan TMPapers in this archive, Carey DJPapers in this archive, Garcia CKPapers in this archive, Stewart DRPapers in this archive, Savage SAPapers in this archive
Abstract
Pathogenic germline variants in telomerase (TERT) cause telomere biology disorders (TBDs) and are associated with bone marrow failure, pulmonary fibrosis, and other complications. TERT c.3150 G > C (p.K1050N) is frequent in the Ashkenazi Jewish (ASH) population and has been identified in ASH families with TBDs. Whole-genome sequencing of 96 p.K1050N heterozygotes from the UK Biobank and All of Us databases revealed a shared haplotype block, supporting a founder effect. Analyses of 15 additional p.K1050N cases validated this haplotype and identified mitochondrial and Y-STR haplogroups consistent with ASH ancestry. Clinical assessments showed that p.K1050N contributes to TBD phenotypes and shortened telomeres, while population data suggest incomplete penetrance. p.K1050N reduces telomerase activity and processivity, and decreases PCNA expression and BrdU incorporation, impairing cell proliferation. Our findings establish TERT p.K1050N as an ASH founder variant associated with TBDs, underscoring the need for genetic screening and long-term clinical studies. Subject terms: Genetics, Haplotypes, Population genetics, Genetics research
This page indexes the study's public bibliographic record. The full text belongs to the journal; follow the DOI above to read it at the source.